Hesham M. Amin, M.D., M.Sc.

Peer-Reviewed Articles

1. Shen C, Song YH, Xie Y, Wang X, Wang Y, Wang C, Liu S, Xue SL, Li Y, Liu B, Tang Z, Chen W, Song J, Amin HM, Zhou J. Downregulation of HADH promotes gastric cancer progression via Akt signaling pathway. Oncotarget. e-Pub 2017. PMID: 28740010.
2. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. e-Pub 2017. PMID: 28683459.
3. Shi W, George SK, George B, Curry CV, Murzabdillaeva A, Alkan S, Amin HM. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK(+) T-cell lymphoma. Mol Oncol. e-Pub 2017. PMID: 28557340.
4. Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
5. Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. e-Pub 2016. PMID: 27713153.
6. Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. e-Pub 2016. PMID: 27655712.
7. Vishwamitra D, George SK, Shi P, Kaseb AO, Amin HM. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. e-Pub 2016. PMID: 27661006.
8. Hu LL, Zhen H, Zhang XN, Zhou L, Amin HM, Shi P. [Effect of Tyrosine Phosphorylation Sites of Oncogenic Protein NPM-ALK on Cell Cycle and Its Related Mechanisms]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 24(4):1201-5, 2016. PMID: 27531800.
9. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.
10. Mitchell J, Tinkey PT, Avritscher R, Van Pelt C, Eskandari G, Konnath George S, Xiao L, Cressman E, Morris JS, Rashid A, Kaseb AO, Amin HM, Uthamanthil R. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology. e-Pub 2016. PMID: 27305144.
11. Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood 126(14):1699-706, 2015. e-Pub 2015. PMID: 26243778.
12. Vishwamitra D, Curry CV, Shi P, Alkan S, Amin HM. SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein. Neoplasia 17(9):742-54, 2015. PMID: 26476082.
13. Irwin ME, Johnson BP, Manshouri R, Amin HM, Chandra J. A NOX2/Egr-1/Fyn pathway delineates new targets for TKI-resistant malignancies. Oncotarget 6(27):23631-46, 2015. PMID: 26136341.
14. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget 6(25):21193-207, 2015. PMID: 26098859.
15. Yang L, Zhang S, George SK, Teng R, You X, Xu M, Liu H, Sun X, Amin HM, Shi W. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms. Oncotarget 6(17):14953-69, 2015. PMID: 25879451.
16. Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK T-cell lymphoma. Mol Cancer 14:53, 2015. e-Pub 2015. PMID: 25884514.
17. Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma 2(6):23631-23646, 2015. e-Pub 2015. PMID: 27508202.
18. Lamhamedi-Cherradi SE, Santoro M, Ramammoorthy V, Menegaz BA, Bartholomeusz G, Iles LR, Amin HM, Livingston JA, Mikos AG, Ludwig JA. 3D tissue-engineered model of Ewing's sarcoma. Adv Drug Deliv Rev 79-80C:155-171, 2014. e-Pub 2014. PMID: 25109853.
19. Li J, Kurasawa Y, Wang Y, Clise-Dwyer K, Klumpp SA, Liang H, Tailor RC, Raymond AC, Estrov Z, Brandt SJ, Davis RE, Zweidler-McKay P, Amin HM, Nagarajan L. Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response. J Immunol 193(9):4654-62, 2014. e-Pub 2014. PMID: 25238756.
20. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget 5(21):10280-92, 2014. PMID: 25373733.
21. Ma H, Mallampati S, Lu Y, Sun B, Wang E, Leng X, Gong Y, Shen H, Yin CC, Jones D, Amin HM, You MJ, Zweidler-McKay P, Ma Y, Kantarjian HM, Arlinghaus RB, Glassman A, Sun X. The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia. Haematologica 99(10):1591-8, 2014. e-Pub 2014. PMID: 24997151.
22. Huang Z, Fang Z, Zhen H, Zhou L, Amin HM, Shi P. Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma. Leuk Lymphoma 55(8):1876-83, 2014. e-Pub 2014. PMID: 24206093.
23. Ok CY, Wang SA, Amin HM. Leukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entity. Clin Lymphoma Myeloma Leuk 14(4):e123-6, 2014. e-Pub 2014. PMID: 24685107.
24. George SK, Vishwamitra D, Manshouri R, Shi P, Amin HM. The ALK inhibitor ASP3026 eradicates NPM-ALK T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget 5(14):5750-63, 2014. PMID: 25026277.
25. Hamedani FS, Cinar M, Mo Z, Cervania MA, Amin HM, Alkan S. Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma. Leuk Res 38(4):503-8, 2014. e-Pub 2014. PMID: 24486291.
26. Yue Y, Wang Y, He Y, Yang S, Chen Z, Wang Y, Xing S, Shen C, Amin HM, Wu D, Song YH. Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors. PLoS One 9(3):e90992, 2014. e-Pub 2014. PMID: 24608798.
27. Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P. Loss of p53 and altered miR15-a/16-1 MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 28(1):118-28, 2014. e-Pub 2013. PMID: 23608884.
28. Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 37:1271-1277, 2013. e-Pub 2013. PMID: 23962569.
29. Shi B, Vishwamitra D, Granda JG, Whitton T, Shi P, Amin HM. Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Neoplasia 15:669-683, 2013. PMID: 23730215.
30. Zhu H, Vishwamitra D, Curry CV, Manshouri R, Diao L, Khan A, Amin HM. NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism. J Pathol 230:82-94, 2013. e-Pub 2013. PMID: 23338972.
31. Fong EL, Lamhamedi-Cherradi SE, Burdett E, Ramamoorthy V, Lazar AJ, Kasper FK, Farach-Carson MC, Vishwamitra D, Demicco EG, Menegaz BA, Amin HM, Mikos AG, Ludwig JA. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc Natl Acad Sci U S A 110:6500-6505, 2013. e-Pub 2013. PMID: 23576741.
32. Garciarena P, Kamiya-Matsuoka C, Tremont IW, Amin HM, de Groot JF. B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. Neurol Clin Pract 3:532-534, 2013.
33. Singh MM, Irwin, ME, Gao Y, Ban K, Shi P, Arlinghaus RB, Amin HM, Chandra J. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer 118:3433-3445, 2012. e-Pub 2011.
34. Vishwamitra D, Li Y, Wilson D, Manshouri R, Curry CV, Shi B, Tang XM, Sheehan AM, Wistuba II, Shi P, Amin HM. MicroRNA-96 is a posttranscriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol 180:1772-1780, 2012.
35. Jain P, Verstovsek S, Orlowski R, Yap E, Amin HM. An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma. Clin Lymphoma Myeloma Leuk 12:459-462, 2012.
36. Vishwamitra D, Shi P, Wilson D, Manshouri R, Vega F, Schlette EJ, Amin HM. Expression and effects of inhibition of IGF-IR tyrosine kinase in mantle cell lymphoma. Haematologica 96:871-880, 2011.
37. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 28:e633-e636, 2010. e-Pub 2010. PMID: 20733125.
38. Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. J Cell Mol Med 14:1777-1792, 2010.
39. Wang Y, Klumpp S, Amin HM, Liang H, Estrov Z, Zweidler-McKay P, Brandt S, Agulnick A, Nagarajan L. SSBP2 is an in vivo tumor suppressor and regulator of LDB1 stability. Oncogene 29:3044-3053, 2010.
40. Quintas-Cardama A, Amin HM, Kantarjian H, Verstovsek S. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma 51:540-542, 2010.
41. Singh RR, Kim JE, Davuluri Y, Drakos E, Cho-Vega JH, Amin HM, Vega F. Sonic hedgehog signaling pathway contributes to tumor cell survival and proliferation in diffuse large B-cell lymphoma. Leukemia 24:1025-1036, 2010.
42. Shi P, Lai R, Lin Q, Iqbal AS, Young LC, Kwak LW, Ford RJ, Amin HM. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood 114:360-370, 2009.
43. Dien Bard J, Gelebart P, Anand M, Zak Z, Hegazy SA, Amin HM, Lai R. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 175:825-834, 2009.
44. Bard JD, Gelebart P, Amin HM, Young LC, Ma Y, Lai R. STAT3 is a transcriptional factor regulating the gene expression of SALL4. FASEB J 23:1405-1414, 2009.
45. Gelebart P, Zak Z, Anand M, Dien-Bard J, Amin HM, Lai R. Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 23:1836-1846, 2009.
46. Lakshmikuttyamma A, Takahashi N, Pastural E, Torlakovic E, Amin HM, Garcia-Manero G, Voralia M, Czader M, DeCoteau JF, Geyer CR. RIZ1 is a potential CML tumor suppressor that is down-regulated during disease progression. J Hematol Oncol 2:28-33, 2009.
47. Ban K, Gao Y, Amin HM, Howard A, Miller C, Lin Q, Leng X, Munsell M, Bar-Eli M, Arlinghaus RB. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood 111:2904-2908, 2008.
48. Yu Z, Sun B, Kantarjian HM, Keating MJ, Amin HM, Sun X. Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma 49:751-756, 2008.
49. Inamdar KV, Medeiros LJ, Jorgensen JL, Amin HM, Schlette EJ. Bone marrow involvement by marginal zone B-cell lymphomas of different types. Am J Clin Pathol 129:714-722, 2008.
50. Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenecity in ALK+ anaplastic large cell lymphoma. Leukemia 22:1595-1603, 2008.
51. Gelebart P, Anand M, Armanious H, Peters A, Bard JD, Amin HM, Lai R. Constitutive activation of the Wnt canonical pathway in mantel cell lymphoma. Blood 112:5171-5179, 2008.
52. Quintas-Cardama A, Harb AJ, Amin HM, Verstovsek S. Granulocytic sarcoma with massive scalp involvement. Am J Hematol 83:340-342, 2008.
53. Ren Y, Medeiros LJ, Amin HM, Rytting ME, Jorgensen JL, Chen W. Unusual expression of CD94 on CD8+ TCR-alpha beta T cells in infectious mononucleosis. Ann Diagn Pathol 11:55-60, 2007. PMID: 17240309.
54. Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol 212:402-410, 2007.
55. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE, Amin HM, Ward DC, Ma Y. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci USA 104:10494-10499, 2007.
56. Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Drakos E, Amin HM, Rassidakis GZ. c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood 107:2544-2547, 2006. PMID: 16304056.
57. Oyarzo MP, Drakos E, Atwell C, Amin HM, Medeiros LJ, Rassidakis GZ. Intrinsic apoptotic pathway in anaplastic large cell lymphoma. Hum Pathol 37:874-882, 2006. PMID: 16784988.
58. Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol 19:1585-1592, 2006. PMID: 16998462.
59. Dien J, Amin HM, Chiu N, Wong W, Frantz C, Chiu B, Mackey JR, Lai R. Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 169:633-642, 2006. PMID: 16877361.
60. Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108:2796-2803, 2006. PMID: 16825495.
61. Han Y, Amin HM, Frantz C, Franko B, Lee J, Lin Q, Lai R. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 20:1602-1609, 2006. PMID: 16871283.
62. Lai R, Lefresne SV, Franko B, Hui D, Mirza I, Mansoor A, Amin HM, Ma Y. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Mod Pathol 19:1498-1505, 2006. PMID: 16980950.
63. Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, Lai R, Ritz J, Krause DS, Chai L. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 108:2726-2735, 2006. PMID: 16763212.
64. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108:2407-2415, 2006. PMID: 16763206.
65. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Jr, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 107:2730-2740, 2006. PMID: 17063503.
66. Shi X, Franko B, Frantz C, Amin HM, Lai R. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol 135:26-32, 2006. PMID: 16939498.
67. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR, Amin HM. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167:969-980, 2005. PMID: 16192633.
68. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70:700-713, 2005. PMID: 16023083.
69. Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 19:1567-1572, 2005. PMID: 16049515.
70. Rassidakis GZ, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R, Claret FX, Medeiros LJ, Amin HM. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 105:827-829, 2005. PMID: 15374880.
71. Lai R, Rassidakis GZ, Lin Q, Atwell C, Medeiros LJ, Amin HM. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Hum Pathol 36:939-944, 2005. PMID: 16153455.
72. Han XY, Lin P, Amin HM, Ferrajoli A. Postsplenectomy cytomegaloviral mononucleosis: marked lymphocytosis, TCRgamma gene rearrangements, and impaired IgM response. Am J Clin Pathol 123:612-617, 2005. PMID: 15743745.
73. Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A, McDonnell TJ, Amin HM, Medeiros LJ. MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum Pathol 35:1095-1100, 2004. PMID: 15343511.
74. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23:5426-5434, 2004. PMID: 15184887.
75. Lai R, Rassidakis GZ, Medeiros LJ, Ramdas L, Goy AH, Cutler C, Fujio Y, Kunisada K, Amin HM, Gilles F. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Am J Pathol 164:2251-2258, 2004. PMID: 15161657.
76. Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurgers K, Remache YK, Vega F, Goy AH, Gilles F, Medeiros LJ. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. Leukemia 18:1872-1878, 2004. PMID: 15385932.
77. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O'Connor SL, Keating MJ, Lai R. Characterization of four mantle cell lymphoma cell lines: establishment of an in vitro study model. Arch Pathol Lab Med 127:424-31, 2003. PMID: 12683869.
78. Khoury JD, Amin HM, Jorgensen JL, Ostrowski ML, Bloom MG, Medeiros LJ. Composite thymoma and chronic lymphocytic leukemia/small lymphocytic lymphoma involving the anterior mediastinum. Arch Pathol Lab Med 127:E76-E79, 2003. PMID: 12562258.
79. Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM, Lai R. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res 9:3692-3699, 2003. PMID: 14506160.
80. Amin HM, Medeiros LJ, Manning JT, Jones D. Dissolution of the lymphoid follicle is a feature of the HHV8+ variant of plasma cell Castleman's disease. Am J Surg Pathol 27:91-100, 2003. PMID: 12502931.
81. Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 102:1866-1868, 2003. PMID: 12730116.
82. Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, Rassidakis GZ, O'Connor SL, McDonnell TJ, Lai R. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 22:5399-5407, 2003. PMID: 12934099.
83. Amin HM, McLaughlin P, Rutherford CJ, Abruzzo LV, Jones D. Cutaneous and systemic plasmacytosis in a patient of Asian descent living in the United States. Am J Dermatopathol 24:241-245, 2002. PMID: 12140441.
84. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, Alkan S. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115:279-286, 2001. PMID: 11703322.
85. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 115:287-297, 2001. PMID: 11703323.
86. Ergin M, Denning MF, Izban KF, Amin HM, Martinez RL, Saeed S, Alkan S. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp Hematol 29:1082-1090, 2001. PMID: 11532349.
87. Amin HM, Petruzzelli GJ, Husain AN, Nickoloff BJ. Primary malignant melanoma of the larynx. Arch Pathol Lab Med 125:271-273, 2001. PMID: 11175650.
88. Amin HM, Perlman JI, Close TW, Collins SL, Thomas C. Sclerosing orbital pseudotumor with involvement of the optic nerve. Ophthalmic Practice 19:350-355, 2001.
89. Amin HM, Ergin M, Denning MF, Quevedo ME, Alkan S. Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia. Br J Haematol 110:552-562, 2000. PMID: 10997964.
90. Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost 6:71-76, 2000. PMID: 10775025.
91. Horn PC, Webster DA, Amin HM, Mascia MF, Werner FW, Fortino MD. The effect of hyperbaric oxygen on medial collateral ligament healing in a rat model. Clin Orthop Relat Res 360:238-242, 1999. PMID: 10101330.
92. Amin HM, Candel AG, Husain AN. Pathologic quiz case. A 22-year-old man with an abdominal mass. Arch Pathol Lab Med 123:541-543, 1999. PMID: 10383811.
93. Sugimori K, Amin HM, Esposito BF, Seedat MS, Camporesi EM. Effect of slow versus fast desaturation on the ventilatory response to hypoxia. J Med 27:277-292, 1996. PMID: 9151197.
94. Ferrario L, Amin HM, Sugimori K, Camporesi EM, Hakim TS. Site of action of endogenous nitric oxide on pulmonary vasculature in rats. Pflugers Arch 432:523-527, 1996. PMID: 8766013.
95. Amin HM, Kaniewski WS, Cohen D, Camporesi EM, Hakim TS. Effects of acute exposure to hyperbaric oxygen on the rheology and morphology of the red blood cells in the rat. Microvasc Res 50:417-428, 1995. PMID: 8583954.
96. Amin HM, Hakim TS, Camporesi EM. Hematological alterations after acute exposure to hyperbaric oxygen in rats. Clin Exp Pharmacol Physiol 22:21-27, 1995. PMID: 7768031.
97. Amin HM, Sopchak AM, Esposito BF, Henson LG, Batenhorst RL, Fox AW, Camporesi EM. Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil. J Pharmacol Exp Ther 274:34-39, 1995. PMID: 7616418.
98. Amin HM, Omran SA, El-Bassuoni NE, El-Kaliouby AH, El-Ashmawy SA. Assessment of factors II, VII, IX, X, and protein C in hepatosplenic schistosomiasis. Haemostasis 24:22-26, 1994. PMID: 7959352.
99. Amin HM, Sopchak AM, Foss JF, Esposito BF, Roizen MF, Camporesi EM. Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg 78:701-705, 1994. PMID: 8135389.
100. Omran SA, Amin HM, El-Bassiouni NE, Essawy FM, Toiema SM. Vitamin K dependent coagulation proteins in endemic hepatosplenomegaly in Egypt. J Clin Pathol 47:502-504, 1994. PMID: 8063929.
101. Amin HM, Cigada M, Fordyce WE, Camporesi EM. Noninvasive monitoring of respiratory volume. Experimental evaluation of a breath monitoring device. Anaesthesia 48:608-610, 1993. PMID: 8346778.
102. Amin HM, Cigada M, Hakim TS, Camporesi EM. Pulmonary mechanical and vascular responses after acute hyperbaric oxygen exposure. Can J Physiol Pharmacol 71:592-596, 1993. PMID: 8306197.
103. Omran SA, Amin HM, El-Bassiouni NE, Essawy FM, Toima SM, El-Kaliouby AH, El-Ashmawy SA. Study of some vitamin K-dependent coagulation proteins in hepatosplenic schistosomiasis. Egypt J Haematol 18:39-48, 1993.

Invited Articles

1. Shi P, Amin HM. JAK3 (Janus Kinase 3 or Just Another Kinase 3). Atlas Genet Cytogenet Oncol Haematol:http://atlasgeneticsoncology.org/Genes/JAK3ID41032ch19p13.html, 2007.
2. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 110(2259-2267), 2007.

Abstracts

1. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Granda JG, Zheng H, Klevesath MB, Kohler K, Bladt F, Johne A, Kurzrock R. MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial. Cancer Res, 2016.
2. Irwin ME, Manshouri R, Johnson B, Amin HM, Chandra J. Targeting Egr-1 is an effective strategy for overcoming kinase inhibitor resistance in CML. Cancer Res, 2016.
3. Abdel-Wahab R, Lacin S, Shalaby AS, Hassan M, Xiao L, Morris J, Amin HM, Kaseb AO. Impact of integrating insulin-like growth factor-1 (IGF-1) in model for end stage liver disease (MELD) scores on predicting hepatocellular carcinoma patients’ survival. ASCO, 2016.
4. Abdel-Wahab R, Lacin S, Shalaby AS, Hassan M, Xiao L, Morris J, Amin HM, Kaseb AO. Integrating insulin-like growth factor-1 (IGF-1) score into Barcelona Clinic Liver Cancer and Cancer of the Liver Italian Group (CLIP) scores. ASCO, 2016.
5. Lacin S, Abdel-Wahab R, Hassan M, Shalaby AS, Amin HM, Wolff RA, Yao JC, Mistry A, Feng JD, Ohtomo T, Kaseb AO. Evaluating clinical and prognostic implications of Glypican 3 in hepatocellular carcinoma. ASCO, 2016.
6. Hassan M, Abdel-Wahab R, Kaseb AO, Shalaby A, Botrus G, Lacin S, Morris JS, Amin HM, Wolff RA, Hwang JP, Li D, Torres HA, Shalaby A, Lenzi R, Yao JC, Joss JA, Jalal PK, Khaderi S, Ballard K, Hawk E. Hepatocellular carcinoma screening in high-risk populations in the United States. The Liver Meeting, AASLD, 2016.
7. HHassan M, Abdel-Wahab R, Wolff RA, Botrus G, Shalaby A, Li D, Torres HA, Morris JS, Ballard K, Hawk E, Shalaby A, Amin HM, Yao JC, Lenzi R, Joss JA, Jalal PK, Khaderi S, Lacin S, Kaseb AO. Growth hormone and hepatocellular carcinoma. The Liver Meeting, AASLD. The Liver Meeting, AASLD, 2016.
8. Raghav KPS, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom BM, Talasaz AA, Overman MJ, Shaw KR, Meric-Bernstam F, Maru DM, Eng C, Hong DS, Kopetz S. Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC). J Clin Oncol, 2015.
9. Falchook GS, Kurzrock R, Amin HM, Fu S, Piha-Paul SA, Janku F, Zheng HX, Sarholz B, Johne A, Hong DS. Efficacy, safety, biomarkers and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J). J Clin Oncol, 2015.
10. Abdel-Wahab R, Eid SM, Hassan M, Xiao L, Lee JS, Cheung SH, Hassabo HM, Shalaby AS, Essa HH, Mossad E, Raghav KS, Rashid A, Wolff RA, Morris J, Amin HM, Kaseb AO. International validation of an IGF-PCT scoring system for assessing hepatic reserve in hepatocellular carcinoma. J Clin Oncol, 2015. PMID: 26098859.
11. Bladt F, Jaehrling F, Friese-Hamim M, Falchook GS, Amin HM, Klevesath MB, Blaukat A. Development of a sensitive assay for measuring pharmacodynamic modulation of c-Met in biopsies. AACR Annual Meeting 2014, 2014.
12. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Granda JG, Zheng H, Klevesath MB, Kohler K, Bladt F, Johne A, Kurzrock R. Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol, 2014.
13. Vishwamitra D, Curry CV, Alkan S, Shi P, Amin HM. Decreased levels of the transcription factors Ik-1 and MZF1 contribute to upregulation of IGF-IR expression in NPM-ALK+ T-cell anaplastic large-cell lymphoma. Proceedings of The American Association for Cancer Research Conference on Hematologic Malignancies: Translating Discoveries To Novel Therapeutics, 2014.
14. Yang L, Zhang S, Liu H, Amin HM, Shi W. Combined targeting of Notch1 and proteasome as an effective strategy to suppress T-cell leukemia/lymphoma. Proceedings of The American Association for Cancer Research Conference on Hematologic Malignancies: Translating Discoveries To Novel Therapeutics, 2014.
15. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Zheng H, Bladt F, Johne A, Kurzrock R. First-in-human phase I trail assessing the highly selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors. European Society for Medical Oncology Congress, 2014.
16. Shi W, George SK, Curry CV, Alkan S, Amin HM. TrkA, a novel binding partner of NPM-ALK oncogenic tyrosine kinase, facilitates the survival of T-cell anaplastic large-cell lymphoma. 56th ASH Annual Meeting and Exposition Abstracts and Program, 2014.
17. Vishwamitra D, Curry CV, Alkan S, Shi P, Amin HM.. SUMOylation sustains the stability of NPM-ALK oncogenic protein and facilitates its nuclear accumulation in T-cell anaplastic large-cell lymphoma. 56th ASH Annual Meeting and Exposition Abstracts and Program, 2014.
18. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Granda JG, Zheng H, Klevesath MB, Kohler K, Bladt F, Johne A, Kurzrock R. Results of the first-in-human phase I trial assessing the oral selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors. The 52nd Annual Meeting of Japanese Society of Clinical Oncology, 2014.
19. Irwin ME, Manshouri R, Johnson B, Amin HM, Chandra J. Targeting Egr-1 is an effective strategy for overcoming kinase inhibitor resistance in CML. AACR Annual Meeting 2014, 2014.
20. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Janku F, Granda JG, Zheng H, Klevesath MB, Kohler K, Bladt F, Johne A, Kurzrock R. MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial. AACR Annual Meeting 2014, 2014.
21. Falchook GS, Hong D, Amin HM, Fu S, Piha-Paul SA, Janku F, Subbiah V, Naing A, Wheler JJ, Klevesath MB, Kohler K, Johne A, Bladt F, Kurzrock R. Phase I study of oral selective c-Met inhibitor EMD 1214063 in patients with advanced solid tumors. J Clin Oncol 31(Suppl.):2506, 2013.
22. Hamedani FS, Mo Z, Amin HM, Cervania M, Alkan S.. Crizotinib, a novel inhibitor of ALK, induces apoptosis and downregulation of pSTAT3 in ALK+ anaplastic large cell lymphoma. United States and Canadian Academy of Pathology 102nd Annual Meeting Program Book, 2013.
23. Cinar M, Hamedani FS, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly expressed in mantle cell lymphoma and its attenuation by Ibrutnib induces apoptosis of mantle cell lymphoma cells. United States and Canadian Academy of Pathology 102nd Annual Meeting Program Book:177, 2013.
24. Raymond A, Liang H, Liang S, Lu Y, Davis RE, Amin HM, Nagarajan L. c-REL is a transcriptional target of homeobox gene mesoderm inducer in Xenopus Like 1 (MIXL1). Keystone Symposia: Myeloid cells: regulation and inflammation:72, 2013.
25. Fong ELS, Lamhamedi-Cherradi S-E, Burdett E, Ramamoorthy V, Lazar AJ, Kasper FK, Farach-Carson MC, Vishwamitra D, Demicco EG, Menegaz B, Amin HM, Ludwig JA, Mikos AG. Engineering a three-dimensional in vitro model of bone sarcoma for drug-testing. Society for Biomaterials Annual Meeting and Exposition Final Program:48, 2013.
26. Raghav KPS, Amin HM, Wang W, Manyam GC, Broom BM, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark for epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. J Clin Oncol 31(Suppl.):3529, 2013.
27. Vishwamitra D, George SK, Manshouri R, Shi P, Amin HM. In vitro and in vivo anti-tumor activity of the selective ALK inhibitor ASP3026 against NPM-ALK+ T-cell anaplastic large-cell lymphoma. Proceedings of the New American Association for Cancer Research Special Conference on Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes:87, 2013.
28. Ng DP, Liang CS, Tian T, Yin C, Young KH, Jorgensen JL, Hoehn D, Sargent R, Miranda RN, Amin HM, You J, Schlette E, Lin P. Assessing minimal disease in plasma cell neoplasms: a comparison between multicolor flow cytometry and immunohistochemistry. Mod Pathol 25:357A, 2012.
29. Amin HM, Falchook GS, Fu S, Hong DS, Tsimberidou AM, Naing A, Wheler JJ, Piha-Paul SA, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. First-in-human phase I dose-escalation study of the oral selective c-Met inhibitor EMD 1204831 in patients with advanced solid tumors. J Clin Oncol 30(Suppl.):3107, 2012.
30. Falchook GS, Hong DS, Amin HM, Fu S, Piha-Paul SA, Klevesath MB, Jego V, Johne A, Stinchi S, Kurzrock R. Phase I dose-escalation study of oral selective c-Met inhibitor EMD 1214063 in patients with advanced solid tumors. Ann Oncol 23:444PD, 2012.
31. Falchook GS, Naing A, Fu S, Amin HM, Piha-Paul SA, Hong DS, Tsimberidou AM, Wheler JJ, Janku F, Klevesath MB, Jego V, Johne A, Kurzrock R. A phase I dose-escalation study of EMD 1214063, an oral selective cMet inhibitor, in patients with advanced solid tumors. Japanese Society of Medical Oncology Book of Abstracts:ISA-1, 2012.
32. Vishwamitra D, Shi P, Amin HM. MicroRNA-30 family functions as a tumor suppressor by inducing posttranscriptional downregulation of IGF-IR expression. Keystone Symposia: MicroRNAs and non-coding RNAs and cancer:228, 2011.
33. Li Y, Shi P, Amin HM. MicroRNA-96 is a posttranscriptional suppressor of anaplastic lymphoma kinase expression in human cancer. Proceedings of the American Association for Cancer Research 102nd Annual Meeting:3996, 2011.
34. Falchook GS, Fu S, Amin HM, Tsimberidou AM, Hong DS, Naing A, Klevesath MB, Mattiacci MR, Johne A, Kurzrock R. Phase I dose-escalation study of the oral selective c-Met inhibitor EMD 1204831 in patients with advanced solid tumours. Eur J Cancer 47:S158, 2011.
35. Falchook GS, Fu S, Amin HM, Piha-Paul SA, Hong DS, Naing A, Klevesath MB, Mattiacci MR, Di Cara A, Kurzrock R. A phase I dose-escalation study of EMD 1214063, an oral selective c-Met inhibitor, in patients with advanced solid tumours. Eur J Cancer 47:S158, 2011.
36. Li J, Klumpp S, Amin HM, Liang H, Brandt SJ, Nagarajan L. Sequence specific single stranded DNA binding protein (SSBP2) is a regulator of hematopoietic stem cell function. Blood 118:1384, 2011.
37. Zhu H, Amin HM. MPM-ALK oncogene upregulates the expression of inducible nitric oxide synthase in T-cell lymphoma through a STAT3/microRNA-26a-dependent mechanism. Blood 118:1383, 2011.
38. Amin HM. NPM-ALK+ T-cell lymphoma as a model for developing cancer therapeutics. 2nd International Conference on Drug Discovery and & Therapy Book of Abstracts:9, 2010.
39. Vishwamitra D, Manshouri R, Wilson D, Shi P, Amin HM. Expression and effects of inhibition of IGF-IR tyrosine kinase in mantle cell lymphoma. Keystone Symposia: New paradigms in cancer therapeutics:84, 2010.
40. Naing A, LoRusso P, Gupta S, Benjamin RS, Rohren E, Chen HX, Doyle L, Berry DA, Amin HM, Kurzrock R. Dual inhibition of IGFR and mTOR pathways. J Clin Oncol 28:7s, 2010.
41. Falchook GS, Wheeler JJ, Tannir NM, Naing A, Jackson E, Hong D, Lawhorn KN, Ng C, Amin HM, Kurzrock R. Hypoxia-inducible facror 1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol 27:159s, 2009.
42. Mattiuzzi G, Amin HM, Kantarjian H, Garcia-Manero G, Cortes J. Baseline serum ferritin predicts rate of infection in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome. Blood 114:644, 2009.
43. Sun B, Mallampati S, Gong Y, Wang D, You MJ, Amin HM, Ma Y, Rajewsky K, Lefebvre V, Sun X. Conditional knockout of Sox4 markedly affects B lymphopoiesis in adult mice. Blood 114:994, 2009.
44. Naing A, Kurzrock R, Chen H, Hong DS, Falchook G, Doyle L, Lawhorn K, Burger AM, Ng C, Amin HM, LoRusso PM. Multicenter phase I clinical trial of an insulin like growth factor (IGF-R) inhibitor (IMC-A12) in combination with a mammalian target of rapamycin (mTOR) inhibitor (CCI-779) to overcome resistance to mTOR inhibition. Mol Cancer Ther 8:B61, 2009.
45. Konoplev S, Nguyen M, Huang X, Rassidakis GZ, Garcia-Manero G, Yin CC, Amin HM, Schlette E, Lin P, Vega-Vazquez F, Admirand J, Huh Y, You J, Jorgensen JL, Kantarjian HM, Medeiros LJ, Bueso-Ramos C. Cytoplasmic expression of nucleophosmin does not predict favorable prognosis in AML patients. Mod Pathol 21:260A, 2008.
46. Shi P, Lai R, Gergely M, Arlinghaus RB, Amin HM. Expression and biological significance of type I insulin-like growth factor receptor tyrosine kinase in chronic myeloid leukemia. Proceedings of the American Association for Cancer Research 99th Annual Meeting:2376, 2008.
47. Mallampati S, Sun B, Gong Y, Wang E, You MJ, Amin HM, Ma Y, Shen H, Zweidler-McKay P, Jones D, Yin C, Glassman A, Kantarjian HM, Arlinghaus RB, Sun X. Rooting into the soil, a model for the role of Sox4 in leukemia. Blood 112:1298, 2008.
48. Amin HM, Inamdar KV, Medeiros LJ, Schlette EJ. Intrasinusoidal infiltration is more frequent in splenic marginal zone lymphoma, but lymphoid follicle formation is common in all types of marginal zone lymphoma. Mod Pathol 20:233A, 2007.
49. Shi P, Lin Q, Iqbal AS, Lai R, Amin HM. Functional interactions between IGF-IR tyrosine kinase and NPM-ALK oncogene identify IGF-IR signaling as a therapeutic target in T-cell ALK-positive anaplastic large-cell lymphoma. Making Connections: A Canadian Cancer Research Conference Celebrating NCIC’s 60th Anniversary Book of Abstracts:206-207, 2007.
50. Ma Y, Yang J, Kong N, Amin HM, Chai L. The expression of SALL4, a newly identified stem cell factor, is correlated with chronic myeloid leukemia disease progression. Blood 110:857A, 2007.
51. Yu Z, Sun B, Kantarjian HM, Amin HM, Sun X. Protein expression profiling of cytokines/cytokine receptors on purified chronic lymphocytic leukemia cells. Blood 110:251B, 2007.
52. Shi P, Lin Q, Iqbal AS, Kwak LW, Lai R, Amin HM. Functional synergism between IGF-IR tyrosine kinase and NPM-ALK oncogene identifies a novel role of IGF-IR in malignant lymphoma. Mol Cancer Ther 6:3555S, 2007.
53. Lai R, Lefresne SV, Franko BC, Shi X, Hui D, Mirza I, Mansoor A, Amin HM, Ma Y. Somatic hypermutation of the immunoglobulin heavy chain (IgH) gene in mantle cell lymphoma. Mod Pathol 19:235A, 2006.
54. Sun X, Wang E, Jones DM, Shen H, Johnson MM, Issa J-P J, Amin HM, Ginsberg CF, Kantarjian HM, Andreeff M, Kornblau SM, Glassman AB, Arlinghaus RB. SOX4 gene expression in human leukemic and benign hematopoietic cells. Proceedings of the American Association for Cancer Research 97th Annual Meeting:3035, 2006.
55. Amin HM, Qiu L, Lin Q, Kirken RA, Lai R. Autocrine release of interleukin-9 promotes Janus kinase 3-dependent survival of anaplastic lymphoma kinase-positive T/null lymphoma cells. J Immunol 176:S32, 2006.
56. Schlette E, Amin HM, Medeiros LJ. CD21 and CD23 immunohistochemical staining highlights lymphoid follicles in splenic marginal zone lymphomas involving bone marrow. XIII. Meeting for the European Association for Haematopathology Book of Abstracts:18, 2006.
57. Schlette E, Amin HM, Medeiros LJ. Intrasinusoidal pattern of BM involvement in splenic marginal zone lymphoma is infrequent and focal. XIII. Meeting for the European Association for Haematopathology Book of Abstracts:19, 2006.
58. Ma Y, Yang J, Chai L, Liu F, Amin HM. Bmi-1 is a SALL4 target gene in hematopoietic and leukemic cells. Blood 108:410A, 2006.
59. Takahashi N, Pastural E, Lowsky R, Torlakovic E, Czader M, Garica-Manero G, Amin HM, Geyer CR, DeCoteau J. RIZ1 is donwnregulated during CML progression and displays tumor suppressor properties in CML cell lines. Blood 108:605A, 2006.
60. Chandra J, Amin HM, Howard A, Miller CP, Lin Q, Ban K. Fyn upregulation is a novel ROS-dependent mechanism controlling CML growth, progression and imatinib resistance. Blood 108:635A, 2006.
61. Ma Y, Barnett T, Chai L, Yang J, Alipio Z, Lin P, Amin HM, Fink L, Di C, Yan H, Ward D. DEAH-Box splicing factor gene, Prp16 amplification in acute myeloid leukemia. Blood 108:198B, 2006.
62. Lai R, Rodriguez-Galindo C, Navid F, Fuller CE, Amin HM, Dalton J, Jenkins JJ, Khoury JD. STAT3 activation in Ewing sarcoma family of tumors. Mod Pathol 18:17A, 2005.
63. Rosen D, Amin HM, Bast RC, Lai R, Liu J. Clinical significance of pSTAT3 expression in ovarian carcinoma. Mod Pathol 18:201A, 2005.
64. Chai L, Cui W, Yang J, Di C, Amin HM, Ma Y. SALL4, a novel oncogene induces myelodysplastic syndrome and acute leukemia via Wnt/β-catenin pathway. Blood 106:397A, 2005.
65. Lin Q, Prudkin ML, Kantarjian HM, Cortes JE, Lau E, Grammatikakis I, Thomazy VA, Lai R, Amin HM. Role of Jak3 in chronic myeloid leukemia: evidence to identify Jak3 as a potential therapeutic target. Blood 106:804A-805A, 2005.
66. Amin HM, Lai R, Lin Q, Feretzaki M, Grammatikakis I, Medeiros LJ, Rassidakis GZ. JAK3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. Mod Pathol 17:238A, 2004.
67. Amin HM, Rassidakis GZ, Medeiros LJ, Ramdas L, Goy AH, Fugio Y, Kunisada K, Gilles F, Lai R. STAT3 activation contributes to high TIMP-1 expression in ALK-positive anaplastic large cell lymphoma. Mod Pathol 17:238A, 2004.
68. Bano A, Amin HM, Olatonade D, Dabbagh L, Lai R. ZAP70 expression in mantle cell lymphoma. Mod Pathol 17:239A, 2004.
69. Lee J, Ma Y, Franko B, Song X, Rassidakis GZ, Amin HM, Lai R. Expression of SHP1 splicing variant with dominant negative effects in malignant hematopoietic neoplasms. Mod Pathol 17:256A, 2004.
70. Oyarzo MP, Medeiros LJ, Feretzaki M, Amin HM, Rassidakis GZ. Activation of intrinsic apoptotic pathway in anaplastic large cell lymphoma. Mod Pathol 17:264A, 2004.
71. Rassidakis GZ, Feretzaki M, Grammatikakis I, Lin Q, Lai R, Medeiros LJ, Amin HM. Selective inhibition of Akt induces cell cycle arrest and apoptosis in anaplastic large cell lymphoma. Cold Spring Harbor Laboratory: Cancer Genetics and Tumor Suppressor Genes:175, 2004.
72. Li C, Lai R, Lin Q, Rassidakis GZ, Grammatikakis I, Hamilton SR, Amin HM. Inhibition of JAK3-STAT3 signaling pathway induces apoptosis and cell cycle arrest in human colon carcinoma cells. Keystone Symposia: Jaks and Stats: Development to disease:69, 2004.
73. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Medeiros LJ, Lai R. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Keystone Symposia: Jaks and Stats: Development to disease:74, 2004.
74. Amin HM, Pierce SA, Estey EH, Kantarjian HM, O’Brien SM, Giles FJ, Albitar M. Multilineage dysplasia is associated with worse clinical outcome independent of the diagnosis of acute myeloid leukemia or myelodysplastic syndrome. Blood 104:403A-404A, 2004.
75. Amin HM, Pierce SA, Kantarjian HM, Keating MJ, Freireich EJ, Koller CA, Beran M, Albitar M, O’Brien SM, Estey EH. Increased bone marrow erythroid precursors is associated with shorter survival in low-grade myelodysplastic syndromes. Blood 104:651A-652A, 2004.
76. Amin HM, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O’Brien SM, Albitar M. Clinical relevance of peripheral blood blasts in the myelodysplastic syndrome. Blood 102:424A, 2003.
77. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis in acute promyelocytic leukemia with t(15;17). Mod Pathol 15:228A, 2002.
78. Amin HM, Medeiros LJ, Manning JT, Jones D. The plasma cell variant of Castleman’s disease lacks uniform histologic and clinical features. Mod Pathol 15:228A, 2002.
79. Amin HM, Jilani I, Estey EH, Keating MJ, Diaz AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased lymphocyte apoptosis in the myelodysplastic syndrome: implication of a critical role. Blood 100:373A, 2002.
80. Ni H, Ergin M, Huang Q, Qin J-Z, Amin HM, Pooley R, Alkan S. Analysis of NF-κB expression in multiple myeloma (MM): down-regulation of NF-κB induces apoptosis in MM. Mod Pathol 14:173A, 2001.
81. Alkan S, Ergin M, Denning MF, Izban K, Pooley R, Amin HM. Protein kinase C (PKC)-δ is commonly expressed in Hodgkin’s lymphoma (HL) and its inhibition by rottlerin in HL cell line causes apoptosis. Mod Pathol 13:141A, 2000.
82. Amin HM, Ergin M, Denning MF, Quevedo ME, Wrone-Smith T, Huang JC, Alkan S. Characterization of apoptosis induced by protein kinase C inhibitors in retinoic acid sensitive and resistant acute promyelocytic leukemia cell line, NB4. Mod Pathol 13:141A, 2000.
83. Amin HM, Alkan S, Martinez RL, Huang JC. Analysis of Bcl-6 protein in primary B-cell non-Hodgkin’s lymphomas (B-NHLs) involving the gastrointestinal (GI) tract. Mod Pathol 13:142A, 2000.
84. Pooley R, Ergin M, Denning MF, Amin HM, Nand S, Alkan S. Protein kinase C (PKC) in chronic lymphocytic leukemia (CLL): patterns of isoform expression and role in apoptosis. Mod Pathol 13:160A, 2000.
85. Alkan S, Ni H, Ergin M, Huang Q, Qin J-Z, Amin HM, Pooley R. Inhibition of NF-κB induces apoptosis in multiple myeloma cell lines and chronic lymphocytic leukemia. Keystone Symposia: NF-κB regulation and function: from basic research to drug development:95, 2000.
86. Ergin M, Denning MF, Izban KF, Amin HM, Pooley RJ, Martinez RL, Alkan S. Analysis of tyrosine kinase NPM-ALK (p80) in anaplastic large cell lymphoma: inhibition of tyrosine kinase activity induces caspase-dependent apoptosis. Blood 96:341A, 2000.
87. Huang Q, Ergin M, Ni H, Qin J-Z, Amin HM, Alkan S. Inhibition of tyrosine kinase causes apoptosis and down-regulation of NFκB in IL-6 dependent and independent multiple myeloma cells. Blood 96:750A, 2000.
88. Amin HM, Saeed S, Ergin M, Huang Q, Izban KF, Alkan S. Nuclear factor κB (NFκB) is constitutively expressed in acute lymphoblastic leukemia (ALL) and its inhibition induces caspase-dependent but cytochrome C-independent apoptosis. Blood 96:208B, 2000.
89. Amin HM, Ergin M, Denning MF, Saeed S, Alkan S. Expression of protein kinase C (PKC) isoforms and the effect of selective PKC-δ inhibition by rottlerin on the induction of apoptosis in acute promyelocytic leukemia. Blood 96:208B, 2000.
90. Amin HM, Lietz H, Hoppensteadt DA, Walenga JM, Ahmad S, Wolf H, Fareed J. Immuno-quantitation of soluble P-selectin in human plasma: effect of anticoagulant matrix and preliminary clinical data. Thromb Haemost 82(Suppl):354-355, 1999.
91. Amin HM, Lietz H, Hoppensteadt DA, Walenga JM, George M, Ahmad S, Fareed J. Quantitation of soluble P-selectin in human plasma: effect of anticoagulant matrix and preliminary clinical data. FASEB J 12:A1115, 1998.
92. Amin HM, Lietz H, Hoppensteadt DA, Walenga JM, George M, Ahmad S, Fareed J. Immuno-quantitation of soluble P-selectin in human plasma: effect of anticoagulant matrix and preliminary clinical data. Clin Chem 44:A51, 1998.
93. Amin HM, Petruzzelli GJ, Husain AN, Nickoloff BJ. Primary malignant melanoma of the larynx. A case report. Otolaryngol Head Neck Surg 119:P169-P170, 1998.
94. Amin HM, Rothko K, Zeller JA. Stability of four different thromboplastin reagents over 24 hours at 18°C. Thromb Haemost 78(Suppl):622, 1997.
95. Ferrario L, Amin HM, Camporesi EM, Hakim TS. Exhaled nitric oxide in endotoxin-treated rats: isolated perfused lung versus intact animal. FASEB J 10:A96, 1996.
96. Amin HM, Ferrario L, Hakim TS, Camporesi EM. Effect of desferrioxamine versus PEG-superoxide dismutase on increased prostacyclin (PGI2) concentration after acute exposure to hyperbaric oxygen. FASEB J 10:A356, 1996.
97. Webster DA, Horn P, Amin HM, Weissbrich O, Mascia MF, Werner FW. Effect of hyperbaric oxygen exposure on ligament healing in a rat model. Undersea Hyperb Med 23(Suppl):11, 1996.
98. Ferrario L, Amin HM, Weissbrich O, Hakim TS, Camporesi EM. Effect of hyperbaric oxygen exposure on exhaled nitric oxide in a septic rat model. Undersea Hyperb Med 23(Suppl):68, 1996.
99. Amin HM, Ferrario L, Hakim TS, Camporesi EM. Effect of different durations of exposure to hyperbaric oxygen on circulating prostacyclin in the rat. Undersea Hyperb Med 23(Suppl):69, 1996.
100. Amin HM, Ferrario L, Sauro MD, Hakim TS, Camporesi EM. Effect of exposure to hyperbaric oxygen on nitric oxide production in the rat. FASEB J 10:A1018, 1996.
101. Ferrario L, Amin HM, Camporesi EM, Hakim TS. Measurement of expired nitric oxide concentration (eNO) in isolated lung preparation. Anesthesiology 85(Suppl):A1140, 1996.
102. Picone A, Lutz C, Gatto LA, Searles B, Paskanik A, Amin HM, Duesterhoeft D. Cardiopulmonary bypass (CPB) and endotoxin synergistically induce the adult respiratory distress syndrome (ARDS). Chest 110(Suppl):9S, 1996.
103. Ferrario L, Amin HM, Sugimori K, Searles B, Camporesi EM, Hakim TS. Site of action of EDRF on pulmonary vasculature by using the double occlusion technique in the rat. FASEB J 9:A274, 1995.
104. Sugimori K, Ferrario L, Amin HM, Hakim TS, Camporesi EM. Effects of acute hyperbaric oxygen (HBO) exposure on vascular reactivity in isolated rat pulmonary arteries. FASEB J 9:A276, 1995.
105. Amin HM, Ferrario L, Sugimori K, Brennan S, Hakim TS, Camporesi EM. Effect of acute exposure to hyperbaric oxygen and 24 hours of recovery on prostacyclin concentration. FASEB J 9:A424, 1995.
106. O'Leary CE, Amin HM, Gilbert E, Paskanik AM, Hakim TS. Cardiovascular changes during isovolemic hemodilution with different colloid solutions in a swine model. FASEB J 9:A435, 1995.
107. Sugimori K, Amin HM, Ferrario L, Hakim TS, Camporesi EM. Changes in vascular reactivities of isolated aorta and pulmonary artery following acute exposure to hyperbaric oxygen [HBO] and 18 hours of recovery in rats. Undersea Hyperb Med 22(Suppl):63, 1995.
108. Amin HM, Ferrario L, Hakim TS, Camporesi EM. Effects of exposure to hyperbaric oxygen on blood rheology in the rat. Undersea Hyperb Med 22(Suppl):64, 1995.
109. Ferrario L, Amin HM, Sugimori K, Brennan S, Hakim TS, Camporesi EM. Acute exposure to hyperbaric oxygen increases prostacyclin release in the pulmonary circulation. Undersea Hyperb Med 22(Suppl):65, 1995.
110. Amin HM, O'Leary CE, Dracker RA, Camporesi EM, Hakim TS. Hematologic changes during isovolemic hemodilution with human albumin, hetastarch or pentastarch in domestic pigs. FASEB J 8:A902, 1994.
111. Amin HM, Hakim TS, Camporesi EM. Changes in the plasma proteins following acute exposure to hyperbaric oxygen and 24 hours of recovery in rats. Undersea Hyperb Med 21(Suppl):35, 1994.
112. Amin HM, Cohen D, Paskanik AM, Hakim TS, Camporesi EM. Acute exposure to hyperbaric oxygen decreases the deformability of the red blood cells. Undersea Hyperb Med 21(Suppl):80, 1994.
113. Amin HM, Sugimori K, Seedat MS, Esposito BF, Sopchak AM, Camporesi EM. Small doses of midazolam do not depress the ventilatory responses to progressively induced hypoxia. Anesthesiology 81(Suppl):A1411, 1994.
114. Sugimori K, Amin HM, Esposito BF, Mascia MF, Camporesi EM. Effect of slow vs. fast desaturation on ventilatory response to hypoxia. Anesthesiology 81(Suppl):A1413, 1994.
115. Sugimori K, Amin HM, Esposito BF, Seedat MS, Camporesi EM. Effect of slow vs. fast desaturation on ventilatory response to hypoxia in human volunteers. Eighth Annual Charles Ross Research Poster Session Book of Abstracts:111, 1994.
116. Ferrario L, Amin HM, Sugimori K, Searles B, Camporesi EM, Hakim TS. Localization of the site of action of EDRF on pulmonary vasculature by using the double occlusion technique. Eighth Annual Charles Ross Research Poster Session Book of Abstracts:112, 1994.
117. Amin HM, Kaniewski WS, Paskanik AM, Camporesi EM, Hakim TS. Changes in blood rheology following acute exposure to hyperbaric oxygen [HBO]. FASEB J 7:A350, 1993.
118. Amin HM, Kaniewski WS, Hakim TS, Camporesi EM. Hematological changes following acute exposure to hyperbaric oxygen [HBO] and 24 hours of recovery in rats. Undersea Hyperb Med 20(Suppl):66, 1993.
119. Amin HM, Sopchak AM, Esposito BF, Graham CL, Batenhorst RL, Camporesi EM. Naloxone reversal of depressed ventilatory response to hypoxia during continuous infusion of remifentanil. Anesthesiology 78(Suppl):A1203, 1993.
120. Amin HM, Sopchak AM, Esposito BF, Foss JF, Hays-Benedict J, Roizen MF, Camporesi EM. Methylnaltrexone does not reverse morphine-induced depression of hypoxic drive. Anesthesiology 78(Suppl):A1204, 1993.
121. Amin HM, Cohen D, Hakim TS, Camporesi EM. Blood alterations after acute hyperbaric oxygen [HBO] exposure. Crit Care Med 20:A96, 1993.
122. Amin HM, Hakim TS, Camporesi EM. Pulmonary mechanical responses after hyperbaric O2 (HBO) exposure and 24 hours of recovery in rats. Undersea Biomed Res 19(Suppl):32, 1992.
123. Amin HM, Hakim TS, Camporesi EM. Blood viscosity changes after exposure to hyperbaric O2 (HBO) in rats. Undersea Biomed Res 19(Suppl):197, 1992.
124. Amin HM, Hakim TS, Camporesi EM. Blood viscosity increases after acute hyperbaric oxygen [HBO] exposure. Anesthesiology 77(Suppl):A635, 1992.
125. Amin HM, Hakim TS, Camporesi EM. Pulmonary vascular responses after acute hyperbaric oxygen [HBO] exposure. Anesthesiology 77(Suppl):A636, 1992.
126. Cigada M, Amin HM, Hakim TS, Camporesi EM. Abolition of the reflex of hypoxic pulmonary vasoconstriction after exposure to hyperbaric oxygen [Italian]. Minerva Anestesiol 57:979, 1991.
127. Cigada M, Amin HM, Winters T, Hakim TS, Camporesi EM. Pulmonary vasculature after short exposure to hyperbaric oxygen (HBO) in rats. Undersea Biomed Res 18(Suppl):29, 1991.
128. Amin HM, Cigada M, Hakim TS, Camporesi EM. Lung mechanics after short exposure to hyperbaric oxygen (HBO) in rats. Undersea Biomed Res 18(Suppl):30, 1991.

Book Chapters

1. Verstovsek S, Newberry KJ, Amin HM. Philadelphia chromosome-negative myeloproliferative neoplasms. In: The MD Anderson Manual of Medical Oncology. McGraw-Hill Professional: New York, New York, 103-130, 2016.
2. Jain N, Amin HM, Verstovsek S. Philadelphia chromosome negative myeloproliferative neoplasms. In: The MD Anderson Manual of Medical Oncology. 2nd edition. McGraw-Hill Professional: New York, New York, 97-121, 2011.
3. Verstovsek S, El-Ahdab SY, Amin HM. Other myeloproliferative diseases. In: Atlas of Cancer. 2nd edition. Current Medicine Group LLC, Springer: Philadelphia, Pennsylvania, USA, 334-344, 2008.
4. Goy AH, Amin HM, Cabanillas F, Medeiros LJ. Diagnosis and management of other lymphoproliferative disorders. In: Non-Hodgkin’s Lymphomas. Lippincott, Williams, and Wilkins: New York, New York, USA, 657-683, 2004.
5. Huang JC, Amin HM, Alkan S. Chronic myeloproliferative disorders. In: Clinical Laboratory Medicine. 2nd edition. Lippincott, Williams, and Wilkins: New York, New York, USA, 964-984, 2001.
6. Curry JL, Amin HM, Theil KS. Synovial, pleural, and peritoneal fluids. In: Clinical Laboratory Medicine. 2nd edition. Lippincott, Williams, and Wilkins: New York, New York, USA, 501-518, 2001.
7. Hakim TS, Amin HM, Ferrario L, Camporesi EM. Hyperoxia-induced injury in the pulmonary circulation. In: Proceedings of the International Symposium on Update of Hyperbaric Oxygen Therapy. La Commerciale: Fidenza, Italy, 168-173, 1995.

Books (edited and written)

1. McClatchey KD, Amin HM, Curry JL. Clinical Laboratory Medicine Self-Assessment and Review. 2nd edition. Lippincott, Williams, and Wilkins: New York, New York, 2002.

Letters to the Editor

1. Amin HM, Lin Q, Lai R. Jak3 contributes to the activation of ALK and Stat3 in ALK+ anaplastic large cell lymphoma. Lab Invest 86: 417-419, 2006.
2. Hui D, Dabbagh L, Hanson J, Amin HM, Lai R. High ZAP-70 expression correlates with worse clinical outcome in mantle cell lymphoma. Leukemia 20: 1905-1908, 2006.
3. Khoury JD, Rassidakis GZ, Medeiros LJ, Amin HM, Lai R. Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood 104: 1580-1581, 2004.
4. Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O’Brien SM, Giles F, Albitar M. Hairy cell leukemia with large cells: long disease course with adequate response to therapy. Leukemia 18: 1912-1914, 2004.
5. Amin HM, Zeller JA, Shen T, Nassar A. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor VLeiden. Am J Clin Pathol 107: 713-715, 1997.
6. Ma H, Mallampati S, Lu Y, Sun B, Wang E, Leng X, Gong Y, Shen H, Yin C, Jones D, Amin HM, You MJ, Zweidler-McKay P, Ma Y, Kantrajian HM, Arlinghaus RB, Glassman, A, Sun X. Sox4 is essential for initiation and progression of acute lymphoblastic leukemia induced by p190 BCR-ABL. Leukemia.